The Efficacy and Safety of Decitabine in Combination with ATRA, G-CSF and Low Dose Cytarabine(Dlaag Regimen)in Relapsed/Refractory Acute Myeloid Leukemia Not Suitable for Strong Chemotherapy : A Phase 2, Prospective, Single-Arm, Multicenter Study
第一作者机构：[1]Shanghai Jiao Tong Univ, Shanghai Tongren Hosp, Dept Hematol, Sch Med, Shanghai, Peoples R China
推荐引用方式(GB/T 7714)：
Yang Li,Liu Ligen,Zhao Limin,et al.The Efficacy and Safety of Decitabine in Combination with ATRA, G-CSF and Low Dose Cytarabine(Dlaag Regimen)in Relapsed/Refractory Acute Myeloid Leukemia Not Suitable for Strong Chemotherapy : A Phase 2, Prospective, Single-Arm, Multicenter Study[J].BLOOD.2019,134:doi:10.1182/blood-2019-131671.
APA：
Yang, Li,Liu, Ligen,Zhao, Limin,Lu, Yingting,Zhang, Jing&Sun, Lihua.(2019).The Efficacy and Safety of Decitabine in Combination with ATRA, G-CSF and Low Dose Cytarabine(Dlaag Regimen)in Relapsed/Refractory Acute Myeloid Leukemia Not Suitable for Strong Chemotherapy : A Phase 2, Prospective, Single-Arm, Multicenter Study.BLOOD,134,
MLA：
Yang, Li,et al."The Efficacy and Safety of Decitabine in Combination with ATRA, G-CSF and Low Dose Cytarabine(Dlaag Regimen)in Relapsed/Refractory Acute Myeloid Leukemia Not Suitable for Strong Chemotherapy : A Phase 2, Prospective, Single-Arm, Multicenter Study".BLOOD 134.(2019)
医学